Search PubMed⌕ Search

Biomedical subjects

J H Peter

Publications and source records attributed to J H Peter.

185 records · Page 11Linked to original sources
PubMed1978

[Epidemiology of struma in ambulant patients (author's transl)].

The number of regional claims was obtained from data on 2408 patients. By the number of regional claims we mean the number of claims for a defined performance in relation to the population living in a certain region; in the present investigation the first claims for in vivo diagnostic thyroid examinations within the administrative area. We found a great reduction of the regional claims in the country administrative areas surrounding Marburg, which was accompanied by a relative increase in advanced disease findings which included some who should have sought medical advice earlier. The disparities demonstrated also show that conclusions should only be drawn on taking into account the area of origin of the disease statistics from the patient data from the facilities of the Department of Health.

Epidemiologic Methods↗
PubMed1977

[Epidemiological results of the study on tooth destruction carried out at the Marburg dental clinic].

The individual components of the DMF-T-index checked for age and sex were examined in 2655 patients, who first attended the ZMK clinic in Marburg in 1974, as regards their connection with social and geographical origins. Results of a comparative study, which is restricted to dental findings of patients between the ages of 15 and 64 from the town Marburg and the country area Marburg-Biedenkopf are presented. The wisdom teeth are not included.

Adolescent↗
PubMedDate not supplied

Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea.

OBJECTIVE: Hypertension is often seen in obstructive sleep apnea (OSA) and is characterized by increased sympathetic activity, depressed baroreflex and accentuated vascular responsiveness. The objective of this study was to investigate the effects of the new T-selective calcium channel blocker mibefradil on invasively measured blood pressure (BP) and heart rate in hypertensive patients with OSA. METHODS: The present study was a double-blind, randomized and placebo-controlled before and after trial in two parallel groups. Fifty-three men aged 23 69 years with systemic hypertension and OSA were recruited from the Outpatient Department of the Marburg University Sleep Laboratory and hospitalized for 10 days. Mibefradil (50 mg) or placebo were given orally in the morning for 8 days. The main outcome measure was the mean arterial (radial) BP monitored continuously during nocturnal sleep and during standardized daytime physical and psychological performance testing. RESULTS: Mibefradil lowered mean arterial BP and heart rate with (SD) during the entire measurement period compared with placebo: -7.25 (9.59) vs -2.11 (8.43) mmHg (P=0.039) and -4.83 (5.94) vs -1.34 (4.13) bpm (P=0.022), respectively. Both effects were observed during nocturnal sleep and performance testing, including graded exercise. Adverse events did not differ compared with placebo. CONCLUSION: Mibefradil is an effective but well-tolerated antihypertensive that also lowers heart rate over 24 h in OSA, in conditions known to increase BP.

Adult↗